The skin is a complex and important organ that plays a vital role in protecting the body from the environment and maintaining overall health. The US National Institute of Health reports that more than 3000 skin conditions are known to exist. Among these, the most prevalent and long-lasting conditions are skin cancer, psoriasis, acne, atopic dermatitis (AD), and allergic reactions like urticaria. These inflammatory skin diseases are common and can be long-lasting. They are caused by the activation of immune cells in the skin, which release cytokines that recruit other immune cells to the site of inflammation. Acute inflammation is a natural healing process, but chronic inflammation can be harmful.
Due to advancements in drug discovery research, a variety of inflammatory diseases are commonly treated with drugs for chronic inflammation, including Etanercept (Enbrel) a dimeric protein-based and Adalibumab (Humira) a monoclonal antibody-based, self-injectable drugs. It has been discovered that Infliximab (Remicade), an intravenous infusion medication based on monoclonal antibodies, works well for patients who do not respond to previous biologic therapy. Tumor necrosis factor-alpha (TNF-alpha), a protein involved in inflammation, is inhibited by these medications. Serious adverse effects like cancer, allergic reactions, and infections can also be caused by them. TNF-α is a pro-inflammatory cytokine involved in the chronic inflammation and can significantly impact on the metabolism and function of adipose tissue. Both Ixekizumab (Taltz) and Secukinumab (Cosentyx) are biologic medications constructed from monoclonal antibodies that are injected subcutaneously to treat moderate-to-severe plaque psoriasis and psoriatic arthritis. Both of these are monoclonal antibodies targets the cytokine interleukin-17 (IL-17), which is involved in inflammation. Ixekizumab was found to be more successful than Secukinumab in treating psoriatic arthritis in clinical trial. Both medications are typically safe and well-tolerated. Serious side effects, including severe infections, allergic reactions, and liver issues, can occur with severe case treatments. Other monoclonal antibodies based biologic medications such as risankizumab (Skyrizi) , guselkumab (Tremfya) , and tildrakizumab (Ilumya) share similarities with previous discussed biologic medicine in their formulation, use in disease treatment and adverse effects; nonetheless, they all target interleukin-23 (IL-23), a cytokine involved in inflammation. Risankizumab has a somewhat greater rate of total psoriasis lesion eradication. Cytoplasmic tyrosine kinases are known as Janus kinases (JAKs), it connect signal transducers and activators of transcription (STAT) transcription factors to cytokine signaling from membrane receptors. JAK inhibitors, which include the oral medications Upadacitinib (Rinvoq) and Ruxolitinib (Jakafi), function by preventing the action of JAK proteins that are implicated in the inflammatory response. These are safe and typically well-tolerated therapies for psoriasis and psoriatic arthritis. They may result in severe adverse effects like liver issues, blood clots, and dangerous infections. Above discussed injectable biologics drugs are used to treat moderate to severe Psoriasis.
On contrary, Topical corticosteroids (binds to glucocorticoid receptors GRs), Vitamin D analogues (binds to vitamin D receptors VDRs) & Calcineurin inhibitors (binds to calcineurin) are the class of medicine applied directly to the skin in the form of cream and it is known to effectively treat mild to moderate psoriasis. These medicines binds to their specific target protein and down-regulate the gene expression of the target protein hence lead to suppression of the immune system. There are drugs available for the treatment of most common skin inflammation caused by allergic reactions. A human monoclonal antibody called dupilumab which is administered by su...
(All Rights Reserved)